Onglyza boosts glucose control versus solo glyburide

Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes annual meeting demonstrated that Onglyza (saxagliptin) produced significant reductions across all key measures of glucose control studied, fasting plasma glucose and postprandial glucose] when added to a sulfonylurea in patients with inadequately controlled type 2 diabetes.

Co-developed by US drug major Bristol-Myers Squibb and Anglo-Swedish giant AstraZeneca, the investigational selective dipeptidyl peptidase-4 inhibitor was well tolerated over the course of the studies, and significantly more people were able to achieve target A1C of less than 7% versus the comparators.

In one study, after 24 weeks, individuals in the saxagliptin plus glyburide treatment arms demonstrated a significant adjusted mean change in A1C from baseline of -0.5% for the saxagliptin 2.5mg plus GLY group and -0.6% for the 5mg cohort, versus +0.1% for the group up-titrated to a maximum total daily dose of GLY of 15mg (p<0.0001).